Skip to main content
Clinical Trials/NCT03236480
NCT03236480
Unknown
Not Applicable

Dynamic Changes of the Respiratory Microbiota and Its Relationship to Fecal Microbiota in Chronic Obstructive Pulmonary Disease

Peking University People's Hospital1 site in 1 country100 target enrollmentJanuary 1, 2017

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Pulmonary Disease, Chronic Obstructive
Sponsor
Peking University People's Hospital
Enrollment
100
Locations
1
Primary Endpoint
all-cause mortality
Last Updated
8 years ago

Overview

Brief Summary

Patients with chronic obstructive pulmonary disease (COPD) are 2-3 times more likely to occur together with chronic gastrointestinal tract (GIT) diseases, such as inflammatory bowel disease (IBD) or irritable bowel syndrome (IBS). Similarly, despite many patients have no history of acute or chronic respiratory disease, up to 50% of IBD patients and 33% of IBS patients have pulmonary involvement, such as inflammation or impaired lung function. Increasing evidence indicated chronic gut and lung disease share key conceptual features with the disorder and dysregulation of the microbial ecosystem. However, the underlying mechanisms are not well understood.

Our study is aimed to elucidate the intimate relationship between the gastrointestinal tract and respiratory tract, and uncover the mechanisms by which the gut microbiota affects the immune responses in the lungs, and vice versa.

Registry
clinicaltrials.gov
Start Date
January 1, 2017
End Date
January 1, 2019
Last Updated
8 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • admitted to hospital with an exacerbation of COPD;
  • with no history of probiotics taken;
  • the duration of antibiotics treatment before enrollment should be less than 72 hours.

Exclusion Criteria

  • being immunocompromised, including history of glucocorticoid taken for more than 1 month, history of immunosuppressive therapy, history of human immunodeficiency virus (HIV) infection, solid tumor or hematological malignancy;
  • history of long-term nursing home stays;
  • history of recently hospitalized (\<90 days).

Outcomes

Primary Outcomes

all-cause mortality

Time Frame: patients will be followed for 3 months after their remission from hospital

all-cause death after the enrollment

Secondary Outcomes

  • exacerbations(during the 3-month follow-up)

Study Sites (1)

Loading locations...

Similar Trials